Drug Safety Communication (FDA) – Risk of serious heart related problems and cancer (tofacitinib)
Drug Safety Communication (FDA) – Risk of serious heart related problems and cancer (tofacitinib)
Drug Safety Communication (FDA) – Risk of serious heart-related problems and cancer (tofacitinib)
On 04 Feb 2021, the U.S. Food and Drug Administration (FDA) has issued a Drug Safety Communication to the public that preliminary results of Xeljanz, Xeljanz XR (tofacitinib) from a safety clinical trial showed an increased risk of serious heart-related problems and cancer compared to another type of medicine called tumor necrosis factor (TNF) inhibitors.
FDA required the safety trial, which also investigated other potential risks including blood clots in the lungs and death. Those final results are not yet available.
Tofacitinib was first approved in 2012 to treat adults with rheumatoid arthritis (RA) who did not respond well to the medicine methotrexate.
To know more @Click here
Drug Safety Communication (FDA) – Risk of serious heart related problems and cancer (tofacitinib):
https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis?utm_medium=email&utm_source=govdelivery
Top Relevant Posts:
Safety signal (Risk of acute adrenal insufficiency) Hydrocortisone
Drug Safety Alerts UK MHRA (November 2020)
